QPPV.COM KNOWLEDGE ASSESSMENT

Besilesomab: Diagnostic Antibody, Radiopharmaceutical Use and Pharmacovigilance

Test your understanding of the concepts covered by Besilesomab: Diagnostic Antibody, Radiopharmaceutical Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A case involves a suspected event, but the available report omits the Scintimun batch, preparation time, activity, and release checks. What is the most appropriate follow-up priority?

Seek relevant product and preparation traceability information while also pursuing clinical event details. Request only the scan interpretation because batch information is not relevant to a radiopharmaceutical. Reject the case unless every radiopharmacy record is available. Replace the missing details with an assumed standard activity and preparation time.

Question 2 of 10 Why should a case review specifically ask about prior exposure to mouse-derived antibodies or murine radiopharmaceuticals?

Prior exposure proves that any later symptom is caused by besilesomab. Prior exposure may be relevant to immunogenicity, hypersensitivity risk, and interpretation of a subsequent exposure. Prior exposure determines the technetium-99m activity required for every patient. Prior exposure converts the diagnostic product into a therapeutic antibody.

Question 3 of 10 Why should the case record preserve the suspected condition that prompted imaging, the scan’s purpose, and subsequent diagnostic conclusions?

These details prove that the radiopharmaceutical caused any later symptom. They provide diagnostic and exposure context needed to interpret events and distinguish clinical outcomes from imaging findings. They allow the scan to be treated as a definitive diagnosis without other evidence. They replace the need to record radiopharmaceutical preparation and administration.

Question 4 of 10 A patient has received besilesomab previously. Which statement is the most appropriate for a professional reviewing a proposed repeat exposure?

Repeat exposure is always safe if the previous scan was interpretable. Repeat exposure can affect immunogenicity and should be assessed under the current product information. Repeat exposure is prohibited in every circumstance, regardless of the current label. A previous exposure makes HAMA information irrelevant.

Question 5 of 10 A patient’s record contains no information about allergy to mouse antibodies or prior HAMA testing. What is the most appropriate next step when assessing suitability for administration?

Assume the patient is eligible because no positive result is documented. Use the current product information and obtain the relevant history or assessment rather than inferring eligibility from incomplete records. Assume the patient has HAMA and permanently exclude all diagnostic imaging. Proceed and investigate allergy history only if an adverse event occurs.

Question 6 of 10 A patient develops symptoms after receiving 99mTc-besilesomab. Which set of information would best support assessment of whether the event may be related to the product?

Only the final scan interpretation and the patient’s age. Event timing relative to injection, signs and symptoms, examination, treatment, outcome, and relevant clinical context. Only the radiopharmacy’s quality-control result. The suspected diagnosis, without details of the event or administration.

Question 7 of 10 Which description best captures the relationship between besilesomab and technetium-99m in Scintimun use?

Technetium-99m is administered separately after an unlabelled antibody infusion. Besilesomab is labelled with technetium-99m as part of radiopharmaceutical preparation before intravenous administration. Besilesomab is a radioactive isotope that binds directly to granulocytes. Technetium-99m is used only to treat the suspected infection after imaging.

Question 8 of 10 A radiopharmacy identifies a preparation deviation, but there is no evidence that the patient was harmed. How should the issue generally be handled?

Automatically classify the deviation as a patient adverse reaction. Assess it through appropriate quality or radiation-protection processes and preserve any linkage to a clinical event if one occurred. Discard the information because there was no reported patient symptom. Treat it as proof that the scan result is invalid and report a clinical diagnosis.

Question 9 of 10 A report describes suspected osteomyelitis in an adult with diabetes and proposes imaging a diabetic-foot infection using Scintimun. What is the most appropriate regulatory interpretation?

The proposed use is within the current indication because all adult bone infections are included. The current product information excludes diabetic-foot infection, so the proposed use should not be treated as within the stated indication. The use is automatically authorised if another imaging modality is also performed. The indication restriction applies only to therapeutic use, not diagnostic imaging.

Question 10 of 10 A diagnostic report conflicts with another imaging modality, but the patient has no suspected clinical harm. How should the discrepancy be approached in aggregate review?

Count every discordant image as a drug safety event. Assess the issue as a possible diagnostic-performance or technical concern and do not classify it as a safety event without a relevant clinical safety concern. Assume the besilesomab result is correct because it uses a radiolabelled antibody. Remove the case from review because imaging discrepancies cannot be investigated.

QPPV.com

Besilesomab: Diagnostic Antibody, Radiopharmaceutical Use and Pharmacovigilance

Cookie Settings